
Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00.
Shares of BioCryst Pharmaceuticals are trading down 1.62% over the last 24 hours, at $10.94 per share.